Quality Review,NGENLA

The realm of growth hormone therapy is complex, with a significant focus on FDA approved growth hormone peptides. Understanding which peptides have received the FDA's stamp of approval is crucial for individuals seeking safe and effective treatments for various conditions. While the FDA has approved a range of therapeutic agents, it's important to distinguish between FDA approved medications and those that are not.

Historically, the Food and Drug Administration (FDA) has been instrumental in regulating medical treatments. Since 1923, the FDA has approved approximately ten natural peptides for diverse indications. Notably, nine peptides are approved for diabetes, and four growth hormone-releasing hormones have also received FDA clearance. This historical context highlights the long-standing role of peptides in medicine.

When it comes to growth hormone therapy, somatropin is a key player. Somatropin is a synthetic form of human growth hormone (hGH) and is available by prescription. Several brand names are associated with somatropin, including Nutropin, Serostim, Saizen, Zorbtive, Genotropin, Norditropin, Humatrope, Nutropin AQ, and Omnitrope. These formulations are FDA approved for specific uses, primarily to treat conditions such as growth hormone deficiency in both children and adults, as well as other growth-related disorders in children like Turner syndrome and chronic kidney disease. Somatropin injection is used to treat growth failure caused by growth hormone deficiency and other conditions.

In recent years, advancements have led to the development of novel delivery methods. For instance, Sogroya® (somapacitan-beco) was the first FDA approved once-weekly subcutaneous formulation of human growth hormone for adult growth hormone deficiency. Further indications for Sogroya® have expanded its use to appropriate children aged 2.5 years and older. Another significant development is Pfizer's NGENLA™ (somatrogon-ghla), a long-acting, once-weekly human growth hormone analog also FDA approved for therapeutic use. Similarly, lonapegsomatropin-tcgd has received FDA approval for once-weekly treatment of growth hormone deficiency, offering a promising alternative for improved patient outcomes.

It is imperative to recognize that not all compounds marketed as peptides have achieved FDA approval. Many commonly discussed peptides, such as BPC-157, TB-500, MK-677, and IGF-1 LR3, are not FDA approved for therapeutic use. Similarly, Ipamorelin is a growth hormone-releasing peptide (GHRP) that, while known for its potential to stimulate muscle growth and improve recovery, is not FDA approved for compounding; its FDA status was removed in 2023. CJC-1295 is another peptide often promoted for growth hormone release that lacks FDA approval. The FDA considers these unapproved peptides as potentially dangerous due to limited data and posing a public health concern.

The FDA has also taken action regarding the use of unapproved peptides. The FDA views the use of HGH for conditions not approved by the Food and Drug Administration as illegal. Therefore, it is against the law to use HGH for purposes like anti-aging if it hasn't received specific FDA clearance.

For those seeking to stimulate their body's natural growth hormone production without direct replacement, Physician-guided Growth Hormone Releasing Hormone (GHRH) peptide therapy is an option. This form of therapy aims to enhance the body's own GH production.

When considering growth hormone treatments, especially peptides, it is essential to prioritize FDA approved options. While some peptides like GHRP-6 are recognized among the best peptides for muscle growth due to their ability to increase HGH production, their regulatory status remains a key consideration. Sermorelin is FDA-approved to treat growth hormone deficiency in children, underscoring the availability of approved therapeutic peptides for specific pediatric conditions.

In summary, while the landscape of growth hormone and peptide therapy is evolving, understanding which substances are FDA approved is paramount. The FDA has approved several somatropin-based medications and newer weekly formulations like Sogroya and NGENLA, offering legitimate treatment pathways for growth hormone deficiency. However, a significant number of peptides commonly discussed lack FDA approval, and their use should be approached with extreme caution and under strict medical guidance. Always consult with a healthcare professional to determine the most appropriate and safest treatment plan.